MedTrace Logo

Virtual Reality and Whole Body Vibration on Muscle Strength and Balance in Children With DMD

NCT07338812 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-14

No results posted yet for this study

Summary

we measure balance and quadriceps strength in Duchenne muscular dystrophy children after applying virtual reality and whole body vibration

Conditions

  • Duchenne Muscular Dystrophy (DMD)

Interventions

DEVICE

virtual reality

Group (A) had designed physical therapy in form of Warm up with gentle stretching movements to prevent injuries. The lower limb muscles on both sides were stretched for 20 seconds, followed by 20 seconds of relaxation, five times. The quadriceps, hamstrings, anterior tibial group, calf muscles, biceps, and triceps were also contracted isometrically. Every muscle contraction was held for 5 seconds, followed by 5 seconds of relaxation, and the process was repeated five times in addition to virtual reality inform of VR program. Nintendo Wii Fit Balance Board (Nintendo, Kyoto, Japan) was used to perform the exercises. In each session, VR was used for a total of 10 minutes three times per week for three consecutive months.

DEVICE

whole body vibration

Group (B) had the same physical therapy program with WBV (Power Plate Pro 5) for a total of 10 minutes per session. The apparatus was set at 30 Hz frequency, 2 mm amplitude, and 5 minutes of operating time. The children were squatted down completely on a vibrating, side-alternating platform and were told to stay that way throughout the experience, communicating any pain they felt to the researchers. The vibration feature automatically shuts off after 5 minutes. After that, the children took a one-minute break. Then, with the same settings as those used in the squatting position, children stood on the vibration platform for 5 minutes. In each session, WBV was used for a total of 10 minutes three times per week for three consecutive months.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
10 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-11
Primary Completion
2025-05-20
Completion
2025-10-12

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07338812 on ClinicalTrials.gov